Composition for improving sexual life and / or prostate symptoms and preparation method thereof

Abstract

The invention discloses a composition for improving sexual life and / or prostate symptoms and a preparation method thereof. The composition is prepared from the following components in parts by weight: 30 to 50 parts of algal polysaccharides, 15 to 25 parts of phospholipid, 8 to 12 parts of euphausia superba oil, 8 to 12 parts of magnesium oxide, 8 to 12 parts of lycopene, 2 to 4 parts of zinc gluconate, 1 to 3 parts of radix ginseng extract, 0.8 to 1.2 parts of flos sophorae immaturus extract, 0.8 to 1.2 parts of fructus rubi extract, 0.8 to 1.2 parts of mulberry fruit extract, 0.8 to 1.2 parts of fructus lycii extract and 0.8 to 1.2 parts of sodium selenite. By limiting the raw materials and the dosage, under the combined action of the raw materials, the prepared composition can improve erectile, ejaculation and anterior lacrimal gland symptoms, can improve the quality of sexual life, and has no side effect on the body.

Description

Technical Field

[0001] This invention relates to the field of composition technology, and more specifically to a composition for improving sexual life and / or prostate symptoms, and a method for preparing the same. Background Technology

[0002] Premature ejaculation (PE) is a common male sexual dysfunction, defined by the International Society of Sexual Medicine as ejaculation occurring, often or always, within approximately one minute before or after penetration, and the inability to control ejaculation. PE can be classified into primary and secondary types. Primary PE refers to the consistent occurrence of premature ejaculation since the onset of sexual activity. Secondary PE refers to premature ejaculation occurring after normal ejaculation time. The incidence of PE is influenced by multiple factors, including individual and cultural differences, and exhibits significant regional variations. Psychological or mental factors, imbalances in the serotonin neurotransmitter in the central nervous system, hypersensitivity of the glans penis, and genetic variations are considered major causes of PE.

[0003] Many so-called kidney-tonifying and aphrodisiac drugs on the market are either completely ineffective or have questionable efficacy. People take them for a long time without any effect. Some may provide temporary pleasure, but most of them will bring serious side effects, such as facial flushing, vasodilation, and severe headaches. Frequent use can also cause or aggravate sexual dysfunction.

[0004] Prostate symptoms mainly manifest as urinary abnormalities, localized pain, and sexual dysfunction, which may be related to prostatitis, benign prostatic hyperplasia (BPH), or tumors. Urinary abnormalities include urinary frequency, urgency, and increased nocturia, especially frequent nighttime urination, which may be caused by BPH compressing the urethra. Difficulty urinating includes a thin urine stream, urinary hesitancy, and straining; in severe cases, urinary retention may occur. Painful urination or burning sensation: urethral stinging during urination often indicates prostatitis or urinary tract infection. Localized pain or discomfort includes lower abdominal, perineal, or lumbosacral pain, which worsens after prolonged sitting and may be related to chronic prostatitis. Postejaculation pain: some patients experience perineal discomfort during ejaculation. Sexual dysfunction includes erectile dysfunction, decreased libido, or ejaculatory abnormalities (such as hematospermia), which may be related to prostate disease or psychological factors. Therefore, developing a product that can improve prostate symptoms is particularly important. Summary of the Invention

[0005] The purpose of this invention is to provide a composition for improving sexual life and / or prostate symptoms and a method for preparing the same. By limiting the ingredients, the composition of this invention can effectively improve sexual life and prostate symptoms, with significant effects.

[0006] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted:

[0007] A first aspect of the present invention provides a composition for improving sexual function and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0008] 30-50 parts seaweed polysaccharide, 15-25 parts phospholipids, 8-12 parts Antarctic krill oil, 8-12 parts magnesium oxide, 8-12 parts lycopene, 2-4 parts zinc gluconate, 1-3 parts ginseng extract, 0.8-1.2 parts sophora japonica flower extract, 0.8-1.2 parts raspberry extract, 0.8-1.2 parts mulberry extract, 0.8-1.2 parts wolfberry extract, and 0.8-1.2 parts sodium selenite.

[0009] Preferably, the composition comprises the following components in parts by weight:

[0010] 35-45 parts seaweed polysaccharide, 18-22 parts phospholipids, 9-11 parts Antarctic krill oil, 9-11 parts magnesium oxide, 9-11 parts lycopene, 3-4 parts zinc gluconate, 1-2 parts ginseng extract, 0.9-1.1 parts sophora japonica flower extract, 0.9-1.1 parts raspberry extract, 0.9-1.1 parts mulberry extract, 0.9-1.1 parts wolfberry extract, and 0.9-1.1 parts sodium selenite.

[0011] Preferably, the composition comprises the following components in parts by weight:

[0012] 40 parts seaweed polysaccharide, 20 parts phospholipids, 10 parts Antarctic krill oil, 10 parts magnesium oxide, 10 parts lycopene, 3 parts zinc gluconate, 2 parts ginseng extract, 1 part sophora japonica flower extract, 1 part raspberry extract, 1 part mulberry extract, 1 part wolfberry extract, and 1 part sodium selenite.

[0013] Preferably, the seaweed polysaccharide is prepared by the seaweed polysaccharide extraction method of Example 5 in the patent document with patent application number 2024116941916.

[0014] Preferably, the phospholipid is prepared by the process of extracting and enzymatically hydrolyzing soybean phospholipids as described in Example 1 of the patent application document No. 2022100851018.

[0015] Preferably, the Sophora japonica extract is prepared by the method of preparing Sophora japonica extract in Example 3 of the patent application document No. 2024115291200.

[0016] A second aspect of the present invention provides a method for preparing the above-described composition, the method comprising the following steps:

[0017] (a) Weigh each raw material according to the parts by weight;

[0018] (b) Mix the raw materials thoroughly to obtain the composition.

[0019] A third aspect of the present invention provides an preparation for improving sexual function and / or prostate symptoms, the preparation comprising the composition.

[0020] Preferably, the dosage form of the preparation includes tablets, powders, granules, and capsules.

[0021] Compared with the prior art, the beneficial effects of the present invention include at least the following:

[0022] By limiting the amount of each raw material and using the ingredients, this invention enables the prepared composition to improve erection, ejaculation, and pre-lacrimal gland symptoms through the combined action of the raw materials, thereby improving the quality of sexual life, and without any side effects on the body. Attached Figure Description

[0023] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the accompanying drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to scale.

[0024] Figure 1 Details of the subjects in the experimental examples of this invention;

[0025] Figure 2 This is a statistical result of the subjective feeling evaluation scores of the subjects before and after using the product in the experimental examples of this invention;

[0026] Figure 3 This is a statistical result of the scores of subjects in the experimental examples of this invention, including the frequency of penile erection hardness sufficient for vaginal penetration and the usual level of sexual desire or interest during sexual intercourse before and after use.

[0027] Figure 4 This is a statistical score of the frequency with which subjects in the experimental examples of this invention were able to maintain penile erection until the completion of sexual intercourse before and after using the product;

[0028] Figure 5 The scoring results of the subjects in the experimental examples of this invention are the time (stopwatch or clock time) from penile insertion into the vagina to ejaculation during sexual intercourse before and after use;

[0029] Figure 6 This is a statistical result of the subjects' overall satisfaction with their sex life before and after using the testimonials in the experimental examples of this invention, as well as the difficulty in prolonging intercourse during sex.

[0030] Figure 7 This is a statistical result of the frequency of sexual orgasm achieved by the partner and the overall satisfaction rating of the partner with sexual life during the sexual intercourse before and after the subjects used the experimental example of this invention.

[0031] Figure 8 The results are statistical scores of the subjects' confidence in successfully completing sexual intercourse before and after using the invention, as well as the number of times they felt anxious, tense, and uneasy during sexual intercourse.

[0032] Figure 9 The statistical results of the scores of subjects in the experimental examples of this invention, including whether they often had a feeling of incomplete urination before and after use, whether the interval between two urinations was often less than two hours, and whether they had ever had intermittent urination;

[0033] Figure 10 The statistical results of the scores given to the subjects in the experimental examples of this invention before and after use, including whether they had difficulty waiting to urinate, whether their urine stream became thinner, and whether they needed to exert force to start urinating.

[0034] Figure 11 This is a statistical result of the scores of subjects in the experimental examples of this invention, showing how many times they generally need to get up to urinate from falling asleep to waking up in the morning before and after using the product. Detailed Implementation

[0035] The embodiments of the technical solution of the present invention will be described in detail below with reference to the examples. The following embodiments are only used to illustrate the technical solution of the present invention more clearly, and are therefore only examples, and should not be used to limit the scope of protection of the present invention.

[0036] It should be noted that, unless otherwise stated, the technical or scientific terms used in this application should have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.

[0037] This invention provides a composition for improving sexual function and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0038] 30-50 parts seaweed polysaccharide, 15-25 parts phospholipids, 8-12 parts Antarctic krill oil, 8-12 parts magnesium oxide, 8-12 parts lycopene, 2-4 parts zinc gluconate, 1-3 parts ginseng extract, 0.8-1.2 parts sophora japonica flower extract, 0.8-1.2 parts raspberry extract, 0.8-1.2 parts mulberry extract, 0.8-1.2 parts wolfberry extract, and 0.8-1.2 parts sodium selenite.

[0039] By limiting the amount of each raw material and using the ingredients, this invention enables the prepared composition to improve erection, ejaculation, and pre-lacrimal gland symptoms through the combined action of the raw materials, thereby improving the quality of sexual life, and without any side effects on the body.

[0040] In some embodiments, the composition comprises the following components in parts by weight:

[0041] 35-45 parts seaweed polysaccharide, 18-22 parts phospholipids, 9-11 parts Antarctic krill oil, 9-11 parts magnesium oxide, 9-11 parts lycopene, 3-4 parts zinc gluconate, 1-2 parts ginseng extract, 0.9-1.1 parts sophora japonica flower extract, 0.9-1.1 parts raspberry extract, 0.9-1.1 parts mulberry extract, 0.9-1.1 parts wolfberry extract, and 0.9-1.1 parts sodium selenite.

[0042] In one embodiment, the composition comprises the following components in parts by weight:

[0043] 40 parts seaweed polysaccharide, 20 parts phospholipids, 10 parts Antarctic krill oil, 10 parts magnesium oxide, 10 parts lycopene, 3 parts zinc gluconate, 2 parts ginseng extract, 1 part sophora japonica flower extract, 1 part raspberry extract, 1 part mulberry extract, 1 part wolfberry extract, and 1 part sodium selenite.

[0044] In one embodiment, the seaweed polysaccharide is obtained by the seaweed polysaccharide extraction method of Example 5 in the patent document with patent application number 2024116941916.

[0045] In one embodiment, the phospholipid is prepared by the process of extracting and enzymatically hydrolyzing soybean phospholipids as described in Example 1 of the patent application document No. 2022100851018.

[0046] In one embodiment, the Sophora japonica extract is prepared by the method for preparing Sophora japonica extract according to Example 3 in the patent application document No. 2024115291200.

[0047] Another embodiment of the present invention provides a method for preparing the above composition, the method comprising the following steps:

[0048] (a) Weigh each raw material according to the parts by weight;

[0049] (b) Mix the raw materials thoroughly to obtain the composition.

[0050] Another embodiment of the present invention provides an preparation for improving sexual function and / or prostate symptoms, the preparation comprising the composition.

[0051] In one embodiment, the dosage form of the formulation includes tablets, powders, granules, and capsules.

[0052] The technical solution of the present invention will be further described in detail below through specific embodiments.

[0053] Unless otherwise specified, all raw materials used in the following embodiments can be commercially available products. Some of these materials are sourced from the following sources:

[0054] Seaweed polysaccharide: prepared by the seaweed polysaccharide extraction method of Example 5 in the patent application document No. 2024116941916.

[0055] Phospholipids: prepared by the process of extracting and enzymatically hydrolyzing soybean phospholipids as described in Example 1 of the patent application document No. 2022100851018.

[0056] Sophora japonica flower extract: prepared by the method of preparation of Sophora japonica flower extract in Example 3 of the patent application document with patent application number 2024115291200.

[0057] Ginseng extract, raspberry extract, mulberry extract, and wolfberry extract: purchased from Xi'an Xiaocao Botanical Technology Co., Ltd.

[0058] Example 1

[0059] This embodiment is a composition for improving sexual life and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0060] 30 parts seaweed polysaccharide, 25 parts phospholipids, 8 parts Antarctic krill oil, 12 parts magnesium oxide, 8 parts lycopene, 2 parts zinc gluconate, 3 parts ginseng extract, 0.8 parts sophora japonica flower extract, 1.2 parts raspberry extract, 1.2 parts mulberry extract, 1.2 parts wolfberry extract, and 0.8 parts sodium selenite.

[0061] The preparation method of the above composition includes the following steps:

[0062] (a) Weigh each raw material according to the parts by weight;

[0063] (b) Mix the raw materials thoroughly to obtain the composition.

[0064] Example 2

[0065] This embodiment is a composition for improving sexual life and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0066] 50 parts seaweed polysaccharide, 15 parts phospholipids, 12 parts Antarctic krill oil, 8 parts magnesium oxide, 12 parts lycopene, 4 parts zinc gluconate, 1 part ginseng extract, 1.2 parts sophora japonica flower extract, 0.8 parts raspberry extract, 0.8 parts mulberry extract, 0.8 parts wolfberry extract, and 1.2 parts sodium selenite.

[0067] The preparation method of the above composition includes the following steps:

[0068] (a) Weigh each raw material according to the parts by weight;

[0069] (b) Mix the raw materials thoroughly to obtain the composition.

[0070] Example 3

[0071] This embodiment is a composition for improving sexual life and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0072] 35 parts seaweed polysaccharide, 22 parts phospholipids, 9 parts Antarctic krill oil, 9 parts magnesium oxide, 11 parts lycopene, 3 parts zinc gluconate, 2 parts ginseng extract, 0.9 parts sophora japonica flower extract, 1.1 parts raspberry extract, 0.9 parts mulberry extract, 1.1 parts wolfberry extract, and 0.9 parts sodium selenite.

[0073] The preparation method of the above composition includes the following steps:

[0074] (a) Weigh each raw material according to the parts by weight;

[0075] (b) Mix the raw materials thoroughly to obtain the composition.

[0076] Example 4

[0077] This embodiment is a composition for improving sexual life and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0078] 45 parts seaweed polysaccharide, 18 parts phospholipids, 11 parts Antarctic krill oil, 11 parts magnesium oxide, 9 parts lycopene, 4 parts zinc gluconate, 1 part ginseng extract, 1.1 parts sophora japonica flower extract, 0.9 parts raspberry extract, 1.1 parts mulberry extract, 0.9 parts wolfberry extract, and 1.1 parts sodium selenite.

[0079] The preparation method of the above composition includes the following steps:

[0080] (a) Weigh each raw material according to the parts by weight;

[0081] (b) Mix the raw materials thoroughly to obtain the composition.

[0082] Example 5

[0083] This embodiment is a composition for improving sexual life and / or prostate symptoms, the composition comprising the following components in parts by weight:

[0084] 40 parts seaweed polysaccharide, 20 parts phospholipids, 10 parts Antarctic krill oil, 10 parts magnesium oxide, 10 parts lycopene, 3 parts zinc gluconate, 2 parts ginseng extract, 1 part sophora japonica flower extract, 1 part raspberry extract, 1 part mulberry extract, 1 part wolfberry extract, and 1 part sodium selenite.

[0085] The preparation method of the above composition includes the following steps:

[0086] (a) Weigh each raw material according to the parts by weight;

[0087] (b) Mix the raw materials thoroughly to obtain the composition.

[0088] Example 6

[0089] This embodiment is a soft capsule for improving sexual life and / or prostate symptoms, the soft capsule being prepared by sealing the composition of Example 5 into a soft capsule.

[0090] Experimental Example

[0091] This experimental example studies the soft capsule formulation of Example 6. Three capsules (1g composition / capsule) are taken once daily with warm water. Details are as follows:

[0092] 1. Inclusion and exclusion criteria for subjects:

[0093] Selection criteria:

[0094] 1) Healthy Chinese men aged 18-55;

[0095] 2) Individuals with premature ejaculation or prostate disease (questionnaire);

[0096] 3) Physically healthy, with no other chronic diseases or diseases currently being treated;

[0097] 4) Participate in the evaluation voluntarily and sign an informed consent form;

[0098] 5) Willing to comply with all evaluation requirements.

[0099] Exclusion criteria:

[0100] 1) Individuals with abnormal liver and kidney function;

[0101] 2) Individuals with hypertension, hyperlipidemia, or hyperglycemia;

[0102] 3) Those who have used antihistamines in the past week or tried immunosuppressants in the past month;

[0103] 4) Subjects with clinically unhealed inflammatory skin diseases;

[0104] 5) Patients with insulin-dependent diabetes mellitus;

[0105] 6) Patients with asthma or other chronic respiratory diseases who are currently receiving treatment;

[0106] 7) Individuals who have received anti-cancer chemotherapy within the past 6 months;

[0107] 8) Patients with immunodeficiency or autoimmune diseases;

[0108] 9) Patients who have undergone bilateral axillary lymph node dissection;

[0109] 10) Participants in other clinical trial investigators;

[0110] 11) Individuals with highly sensitive constitutions;

[0111] 12) Individuals with other iatrogenic problems that may affect the test results (such as those with coagulation disorders, severe hyperglycemia, hypertension, hyperlipidemia, mental illness, or other serious illnesses).

[0112] 13) Non-volunteer participants or those who cannot complete the prescribed content according to the test requirements.

[0113] Precautions for test takers:

[0114] 1) Use the provided samples as required during testing;

[0115] 2) During the testing period, ensure that other lifestyle and dietary habits are not changed.

[0116] Criteria for quitting midway:

[0117] 1) Not selected (e.g., not meeting the selection criteria or excluded by the exclusion criteria, etc.);

[0118] 2) Participants were determined to be ineligible after being selected (including but not limited to changes in other lifestyle or diet during the evaluation period);

[0119] 3) The participant chooses to withdraw;

[0120] 4) An adverse event or a serious adverse event occurs;

[0121] 5) Loss to follow-up;

[0122] 6) Force majeure;

[0123] 7) Others.

[0124] Subject details are as follows Figure 1 As shown.

[0125] 2. Testing Method:

[0126] 1) International Index of Erectile Function (IIEF-5) Questionnaire;

[0127] 2) Sexual Function Evaluation Scale for Premature Ejaculation Patients (CIPE);

[0128] 3) International Prostate Symptom Scale (I-PSS);

[0129] Liu Weiyi, Zhou Lin, Zhao Hua. Evaluation of cosmetic efficacy (XIII) - Consumer use test [J]. Daily Chemical Industry, 2021, 51(06):485-490;

[0130] 3. Testing process:

[0131] D0:

[0132] 1) Subject information registration, understanding and signing of informed consent forms, and screening of subjects by laboratory technicians according to inclusion and exclusion criteria;

[0133] 2) Laboratory technicians will guide subjects on how to use the samples according to the usage requirements and application sites, and provide written test precautions and usage instructions:

[0134] 3) The subject receives the sample and leaves the laboratory.

[0135] D7:

[0136] Participants completed an online self-assessment questionnaire.

[0137] D14:

[0138] Participants completed an online self-assessment questionnaire.

[0139] D21:

[0140] Participants completed an online self-assessment questionnaire.

[0141] D28:

[0142] Subjects completed an online self-assessment questionnaire, and samples and usage logs were collected.

[0143] Note: D0 refers to the visit before the subject uses the sample, D7 refers to 7 days after the subject uses the sample, D14 refers to 14 days after the subject uses the sample, D21 refers to 21 days after the subject uses the sample, and D28 refers to 28 days after the subject uses the sample.

[0144] 4. Data statistical methods:

[0145] 1) Descriptive statistics:

[0146] Subject self-identity assessment: percentage of respondents expressing agreement;

[0147] Subject self-assessment on a five-point scale: mean, standard deviation, maximum, minimum;

[0148] 2) Difference Analysis:

[0149] SPSS statistical analysis software was used for data analysis. All statistical analyses were performed using two-tailed tests, with a significance level of α = 0.05.

[0150] Instrument measurements: If the measurement conforms to a normal distribution, a paired t-test is used for comparisons before and after the measurement; otherwise, a rank-sum test of two related samples is used.

[0151] Five-point assessment: The self-comparison before and after is performed using the rank-sum test of two relevant samples.

[0152] 5. Test Results

[0153] 1) Participant completion status:

[0154] This study included 30 male participants, and all 30 participants were ultimately selected.

[0155] 2) Feedback on adverse reactions during use:

[0156] Table 1 Results of human trial

[0157]

[0158] Table 2 Standards for Powders that Cause Adverse Skin Reactions

[0159] Classification Skin reaction 0 No response 1 faint erythema 2 Erythema, infiltration, papules 3 Erythema, edema, papules, vesicles 4 Erythema, edema, bullae

[0160] Note: Refer to the grading standards for adverse skin reactions during human trials as specified in the 2015 edition of the "Cosmetic Safety Technical Specifications";

[0161] Results: After 7 days of sample use, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred; after 14 days of sample use, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred; after 21 days of sample use, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred; after 28 days of sample use, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred.

[0162] 3) Subjective feelings and evaluation:

[0163] Table 3. Subjective Evaluation Results (CIPE Score for Sexual Function Evaluation of Premature Ejaculation Patients)

[0164]

[0165] Improvement rate = (Self-assessment score after use - Self-assessment score before use) / Self-assessment score before use * 100%;

[0166] CIPE (Childhood Ejaculation Evaluation Scale) - Score: Full score 50 points. ① 10-34 points confirms premature ejaculation; ② 34-36 points are on the borderline, close to premature ejaculation; ③ 36-50 points confirm no premature ejaculation.

[0167] Table 4. Subjective Experience Evaluation Results (International Prostate Symptom Scale I-PSS Score)

[0168]

[0169]

[0170] Improvement rate = (Self-assessment score before use - Self-assessment score after use) / Self-assessment score before use * 100%;

[0171] The International Prostate Symptom Scale (I-PSS) score ranges from 0 to 35, and is categorized into mild, moderate, and severe symptoms according to the following criteria: 0-7 for mild symptoms, 8-19 for moderate symptoms, and 20-35 for severe symptoms. A total score greater than 1 is required for inclusion in the study group.

[0172] The bar chart of subjective feeling evaluation results is as follows Figure 2 As shown; Figure 2 In the figure, **** indicates a significant difference, P<0.001.

[0173] Depend on Figure 2 As shown in Tables 3 and 4:

[0174] Compared with before use, after 7, 14, 21 and 28 days of sample use, the improvement rates of the CIPE-score on the sexual function evaluation scale for premature ejaculation were 5.21%, 54.76%, 83.30% and 90.66%, respectively, and the differences were statistically significant.

[0175] Compared with before use, after 7, 14, 21 and 28 days of use, the improvement rates of the International Prostate Symptom Scale (I-PSS) score were 16.11%, 22.25%, 38.12% and 47.62%, respectively, and the differences were statistically significant.

[0176] 4) Subjective evaluation of sexual function in patients with premature ejaculation using the CIPE (Children of Premature Ejaculation) questionnaire:

[0177] Subjects were assessed on their usual level of sexual desire or interest, using a rating scale of 1 point: very low; 2 points: low; 3 points: average; 4 points: high; 5 points: very high. The scores were then collected before and 28 days after sample use. The results were then analyzed... Figure 3 As shown;

[0178] During sexual intercourse, the frequency with which penile erection was sufficient for vaginal penetration was scored using a scale of 1 point: almost never; 2 points: a few times; 3 points: about half the time; 4 points: most of the time; 5 points: almost always. The scores were then collected from participants before and 28 days after sample use. Figure 3 As shown;

[0179] During sexual intercourse, the frequency of maintaining an erection until completion of intercourse was assessed using a scoring system: 1 point: almost never; 2 points: a few times; 3 points: about half the time; 4 points: most of the time; 5 points: almost always. The scores were then collected from participants before and 28 days after sample use. The results were then analyzed... Figure 4 As shown;

[0180] During sexual intercourse, the time from penile insertion to ejaculation was scored using a stopwatch or clock. The scoring criteria were: 1 point: extremely short (<30 seconds); 2 points: very short (1 minute); 3 points: short (2 minutes); 4 points: relatively short (3 minutes); 5 points: not short (>3 minutes). The scores were then collected from participants before and 28 days after sample use. The results were then analyzed... Figure 5 As shown;

[0181] The difficulty of prolonging intercourse during sexual activity was assessed using a rating scale: 1 point: very difficult; 2 points: difficult; 3 points: somewhat difficult; 4 points: average; 5 points: no difficulty. The ratings were then collected from participants before and 28 days after sample use. The results were then analyzed... Figure 6 As shown;

[0182] The overall satisfaction level with sexual life was assessed using a rating scale: 1 point: very dissatisfied; 2 points: dissatisfied; 3 points: average; 4 points: satisfied; 5 points: very satisfied. The ratings were then collected before and 28 days after sample use. The results were then analyzed. Figure 6 As shown;

[0183] The overall satisfaction of spouses with their sexual life was assessed using a rating scale: 1 point: very dissatisfied; 2 points: dissatisfied; 3 points: average; 4 points: satisfied; 5 points: very satisfied. The ratings were then collected before and 28 days after sample use. The results were then analyzed. Figure 7 As shown;

[0184] The frequency of sexual intercourse was assessed using a rating scale: 1 point: almost never; 2 points: a few times; 3 points: about half the time; 4 points: most of the time; 5 points: almost always. The ratings were then collected from participants before and 28 days after sample use. The results were then analyzed... Figure 7 As shown;

[0185] The participants were assessed on their confidence in successfully completing sexual intercourse, using a rating scale of 1 point: very low; 2 points: low; 3 points: average; 4 points: confident; 5 points: very confident. The ratings were then collected before and 28 days after sample use. The results were then analyzed. Figure 8 As shown;

[0186] The participants were asked to rate how often they felt anxious, tense, and uneasy during sexual activity, using a rating scale of 1 point: almost always; 2 points: most of the time; 3 points: usually; 4 points: a few times; 5 points: almost never. The ratings were then collected before and 28 days after sample use. The results were then analyzed. Figure 8 As shown;

[0187] Depend on Figures 3-8 It can be known that:

[0188] Compared with before use, after 28 days of sample use, the subjects' self-reported levels of sexual desire or interest, penile erection hardness sufficient for vaginal penetration, frequency of maintaining an erection until completion of intercourse, time from penile penetration to ejaculation, difficulty in prolonging intercourse, overall satisfaction with sexual life, overall satisfaction of their partner with sexual life, frequency of their partner reaching orgasm, confidence in successfully completing sexual intercourse, and frequency of anxiety, tension, and unease during sexual life were all significantly improved, with improvement rates of 71.67%, 84.21%, 85.71%, 48.57%, 91.53%, 87.50%, 103.85%, 116.67%, 118.00%, and 122.45%, respectively.

[0189] 5) Subjective evaluation using the International Prostate Symptom Scale (I-PSS):

[0190] The subjects were assessed on the following criteria: frequency of urinary incontinence, frequency of urination intervals frequently less than two hours, history of intermittent urination, urgency to urinate, weak urine stream, and need for straining to initiate urination. The scoring criteria were as follows: 0 points (none); 1 point (less than once); 2 points (less than half); 3 points (approximately half); 4 points (more than half); 5 points (almost every time). The scores were then statistically analyzed before and 28 days after sample use. Figures 9-10 As shown;

[0191] The number of times a person typically needs to urinate from falling asleep to waking up was assessed using a 5-point scale: 0 points: none; 1 point: 1 time; 2 points: 2 times; 3 points: 3 times; 4 points: 4 times; 5 points: 5 times. The scores were then tallied before and 28 days after sample use. The results were then analyzed. Figure 11 As shown;

[0192] Depend on Figures 9-11 It can be known that:

[0193] Compared to before use, after 28 days of sample use, subjects reported significant improvements in the following: frequent feelings of incomplete urination; intervals between urinations frequently less than two hours; intermittent urination; inability to wait to urinate; weak urine stream; needing to strain to initiate urination; and the frequency of urination from falling asleep to waking up. The improvement rates were 50.00%, 48.48%, 46.83%, 448.00%, 51.56%, 47.01%, and 40.00%, respectively.

[0194] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and specification of the present invention.

Claims

1. A composition for improving sexual function and / or prostate symptoms, characterized in that, The composition comprises the following components in parts by weight: 30-50 parts seaweed polysaccharide, 15-25 parts phospholipids, 8-12 parts Antarctic krill oil, 8-12 parts magnesium oxide, 8-12 parts lycopene, 2-4 parts zinc gluconate, 1-3 parts ginseng extract, 0.8-1.2 parts sophora japonica flower extract, 0.8-1.2 parts raspberry extract, 0.8-1.2 parts mulberry extract, 0.8-1.2 parts wolfberry extract, and 0.8-1.2 parts sodium selenite.

2. The composition according to claim 1, characterized in that, The composition comprises the following components in parts by weight: 35-45 parts seaweed polysaccharide, 18-22 parts phospholipids, 9-11 parts Antarctic krill oil, 9-11 parts magnesium oxide, 9-11 parts lycopene, 3-4 parts zinc gluconate, 1-2 parts ginseng extract, 0.9-1.1 parts sophora japonica flower extract, 0.9-1.1 parts raspberry extract, 0.9-1.1 parts mulberry extract, 0.9-1.1 parts wolfberry extract, and 0.9-1.1 parts sodium selenite.

3. The composition according to claim 1, characterized in that, The composition comprises the following components in parts by weight: 40 parts seaweed polysaccharide, 20 parts phospholipids, 10 parts Antarctic krill oil, 10 parts magnesium oxide, 10 parts lycopene, 3 parts zinc gluconate, 2 parts ginseng extract, 1 part sophora japonica flower extract, 1 part raspberry extract, 1 part mulberry extract, 1 part wolfberry extract, and 1 part sodium selenite.

4. The composition according to any one of claims 1 to 3, characterized in that, The seaweed polysaccharide was prepared by the seaweed polysaccharide extraction method of Example 5 in the patent application document with patent application number 2024116941916.

5. The composition according to any one of claims 1 to 3, characterized in that, The phospholipids were prepared by the process of extracting and enzymatically hydrolyzing soybean phospholipids as described in Example 1 of the patent application document No. 2022100851018.

6. The composition according to any one of claims 1 to 3, characterized in that, The Sophora japonica extract was prepared by the method described in Example 3 of the patent application document No. 2024115291200.

7. A method for preparing the composition according to any one of claims 1 to 6, characterized in that, The preparation method includes the following steps: (a) Weigh each raw material according to the parts by weight; (b) Mix the raw materials thoroughly to obtain the composition.

8. A preparation for improving sexual function and / or prostate symptoms, characterized in that, The formulation comprises the composition according to any one of claims 1 to 6.

9. The preparation for improving sexual function and / or prostate symptoms according to claim 8, characterized in that, The dosage forms of the preparation include tablets, powders, granules, and capsules.

Images